<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100758">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01825759</url>
  </required_header>
  <id_info>
    <org_study_id>West China Hospital</org_study_id>
    <nct_id>NCT01825759</nct_id>
  </id_info>
  <brief_title>Danshen Dropping Pill for Coronary Heart Disease Heart and Artery Structure and Function</brief_title>
  <official_title>The Impact of Compound Danshen Dropping Pill for Coronary Heart Disease With Hypertension Patient Heart and Artery Structure and Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>West China Hospital</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Impact of Compound danshen dropping pill for coronary heart disease (CHD) heart and
      artery structure and function in patients with hypertension
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Compound danshen dropping pill for coronary heart disease (CHD) heart and artery structure
      and function in patients with hypertension.We can accorand the pwv ,IMT and MDA to assess
      the impact of heart and artery structure and function.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Pulse wave velocity</measure>
    <time_frame>one year</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>ankle-brachial index</measure>
    <time_frame>one year</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>intima-media thickness,methyl-di-aide-hyde</measure>
    <time_frame>one year</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Coronary Heart Disease</condition>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>danshen dripping pill</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>danshen dripping pill 27mg ten pills by mouth every 8 hours for one year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>danshen dripping pill</intervention_name>
    <arm_group_label>danshen dripping pill</arm_group_label>
    <other_name>compound danshen dripping pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:coronary heart disease，primary hypertension， -

        Exclusion Criteria:secondary hypertension，diabetes mellitus，chronic renal disease，cardiac
        insufficiency

        -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>chen xi ping, master</last_name>
    <role>Study Director</role>
    <affiliation>organizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>chen xi ping, master</last_name>
    <phone>028-85423352</phone>
    <email>panpei74@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>West China Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>chen xi ping, master</last_name>
      <phone>028-85423352</phone>
      <email>panpei74@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://ClinicalTrials.gov</url>
    <description>ABI</description>
  </link>
  <link>
    <url>http://ClinicalTrials.gov</url>
    <description>IMT</description>
  </link>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>April 5, 2013</lastchanged_date>
  <firstreceived_date>March 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West China Hospital</investigator_affiliation>
    <investigator_full_name>Xiaoping Chen</investigator_full_name>
    <investigator_title>Compound danshen dropping pill for coronary heart disease with hypertension patient heart and artery structure and function</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Dan-shen root extract</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
